Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,216 across all filing types
Latest filing 2025-01-21 Board/Management Inform…
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 16, 2025. It announces changes in the company's senior management, specifically the appointment of a new Chief Commercial Officer and a change in position for another executive. It also details the adoption of an amended and restated inducement plan by the board of directors. The primary focus is on management changes and related governance matters. There are no financial statements or detailed financial performance data included. The document fits the category of announcements related to changes in the company's board of directors or senior management rather than a full annual report, earnings release, or other financial filings. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-01-21 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-01-15 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 10, 2025, by Pacira BioSciences, Inc. It announces preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2024, and includes a press release as an exhibit. The document is relatively short (3415 characters) and primarily serves as a current report to announce financial results, not a full detailed financial report. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. It is not an Annual Report (10-K) or Interim Report (IR) because it does not contain comprehensive financial statements or detailed analysis. It is not a Regulatory Filing (RNS) because it contains substantive financial result announcements. Therefore, the correct classification is Earnings Release (ER).
2025-01-10 English
FORM 4
Director's Dealing
2025-01-07 English
FORM 4
Director's Dealing
2025-01-07 English
FORM 4
Director's Dealing
2025-01-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.